There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cellectis SA (CLLS – Research Report) and Microbot Medical (MBOT – Research Report) with bullish sentiments.
Microbot Medical (MBOT)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Microbot Medical today and set a price target of $8.00. The company’s shares closed last Monday at $1.10, close to its 52-week low of $1.06.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Microbot Medical with a $8.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLLS:
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
- Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
- Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
- Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
